ATE500832T1 - Kombination von zd6474 und pemetrexed - Google Patents

Kombination von zd6474 und pemetrexed

Info

Publication number
ATE500832T1
ATE500832T1 AT06820566T AT06820566T ATE500832T1 AT E500832 T1 ATE500832 T1 AT E500832T1 AT 06820566 T AT06820566 T AT 06820566T AT 06820566 T AT06820566 T AT 06820566T AT E500832 T1 ATE500832 T1 AT E500832T1
Authority
AT
Austria
Prior art keywords
pemetrexed
human
combination
antiangiogenic
warm
Prior art date
Application number
AT06820566T
Other languages
English (en)
Inventor
Stephen Wedge
Anderson Ryan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0526121A external-priority patent/GB0526121D0/en
Priority claimed from GB0610706A external-priority patent/GB0610706D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE500832T1 publication Critical patent/ATE500832T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT06820566T 2005-12-22 2006-12-19 Kombination von zd6474 und pemetrexed ATE500832T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0526121A GB0526121D0 (en) 2005-12-22 2005-12-22 Combination therapy
GB0610706A GB0610706D0 (en) 2006-05-31 2006-05-31 Combination therapy
PCT/GB2006/004750 WO2007071958A2 (en) 2005-12-22 2006-12-19 Combination of zd6474 and pemetrexed

Publications (1)

Publication Number Publication Date
ATE500832T1 true ATE500832T1 (de) 2011-03-15

Family

ID=37814151

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06820566T ATE500832T1 (de) 2005-12-22 2006-12-19 Kombination von zd6474 und pemetrexed

Country Status (19)

Country Link
US (2) US20080269261A1 (de)
EP (1) EP1971338B8 (de)
JP (1) JP5167144B2 (de)
KR (1) KR20080079675A (de)
AT (1) ATE500832T1 (de)
AU (1) AU2006328189B2 (de)
BR (1) BRPI0620140A2 (de)
CA (1) CA2631764A1 (de)
CY (1) CY1111547T1 (de)
DE (1) DE602006020621D1 (de)
DK (1) DK1971338T3 (de)
HR (1) HRP20110360T1 (de)
IL (1) IL191796A0 (de)
NO (1) NO20082567L (de)
NZ (1) NZ568811A (de)
PL (1) PL1971338T3 (de)
PT (1) PT1971338E (de)
SI (1) SI1971338T1 (de)
WO (1) WO2007071958A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (de) * 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
GB0318422D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
HRP20110365T1 (hr) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija azd2171 i pemetrekseda
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy
US20090221615A1 (en) * 2008-02-29 2009-09-03 Guru Reddy Combination anti-cancer agents
JP6182313B2 (ja) 2010-03-08 2017-08-16 スペクトラム ファーマシューティカルズ インコーポレイテッド 癌治療のためのチオキサントンをベースとしたオートファジー阻害剤療法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU743024B2 (en) * 1997-03-05 2002-01-17 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
US7001911B2 (en) * 2000-06-28 2006-02-21 Bristol-Myers Squibb Company Fused cyclic modulators of nuclear hormone receptor function
ATE526019T1 (de) * 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
GB0218526D0 (en) * 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
AU2003249000B2 (en) * 2002-08-09 2007-04-05 Astrazeneca Ab Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
KR20050100683A (ko) * 2003-02-13 2005-10-19 아스트라제네카 아베 5-ｆｕ 또는/및 ｃｐｔ-11과 ｚｄ6474의 병용 요법
EP1648465B1 (de) * 2003-07-10 2010-08-25 AstraZeneca AB Verwendung des chinazolin-derivats zd6474 in kombination mit platinverbindungen und optional ionisierender strahlung bei der behandlung von erkrankungen im zusammenhang mit angiogenese und/oder erhöhter gefässpermeabilität
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
HRP20110365T1 (hr) * 2005-12-22 2011-06-30 Astrazeneca Ab Kombinacija azd2171 i pemetrekseda
PL1971338T3 (pl) * 2005-12-22 2011-07-29 Astrazeneca Ab Połączenie ZD6474 i premetreksedu
WO2008037996A1 (en) * 2006-09-29 2008-04-03 Astrazeneca Ab Combination of zd6474 and bevacizumab for cancer therapy

Also Published As

Publication number Publication date
AU2006328189A1 (en) 2007-06-28
SI1971338T1 (sl) 2011-06-30
KR20080079675A (ko) 2008-09-01
CY1111547T1 (el) 2015-08-05
DE602006020621D1 (de) 2011-04-21
JP5167144B2 (ja) 2013-03-21
BRPI0620140A2 (pt) 2011-11-01
NZ568811A (en) 2011-06-30
WO2007071958A2 (en) 2007-06-28
PL1971338T3 (pl) 2011-07-29
NO20082567L (no) 2008-07-31
DK1971338T3 (da) 2011-05-23
WO2007071958A3 (en) 2008-03-27
EP1971338A2 (de) 2008-09-24
CA2631764A1 (en) 2007-06-28
US20110212978A1 (en) 2011-09-01
IL191796A0 (en) 2008-12-29
HK1123186A1 (en) 2009-06-12
HRP20110360T1 (hr) 2011-06-30
JP2009520783A (ja) 2009-05-28
PT1971338E (pt) 2011-05-09
US20080269261A1 (en) 2008-10-30
AU2006328189B2 (en) 2010-01-21
EP1971338B1 (de) 2011-03-09
EP1971338B8 (de) 2011-09-21

Similar Documents

Publication Publication Date Title
CY1111547T1 (el) Συνδυασμος zd6474 και πεμετρεξεδης
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
CY1111482T1 (el) Συνδυασμος azd2171 και πεμετρεξεδης
MX2007003505A (es) Combinacion que comprende zd6474 e imatinib.
MXPA05008583A (es) Terapia de combinacion de zd6474 con 5-fu y/o cpt-11.
MX2007005356A (es) Terapia de combinacion que comprende zd6474 y un antiadrogenico.
PL1653964T3 (pl) Skojarzone leczenie raka obejmujące AZD2171 i ZD1839
NO20064755L (no) Kombinasjonsterapi
NO20064754L (no) Kombinasjonsterapi
NO20056171L (no) Kombinasjonsterapi
WO2005092384A3 (en) Combination therapy with azd2171 and a platinum anti-tumour agent
WO2007003933A3 (en) Combination therapy of cancer with azd2171 and gemcitabine

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1971338

Country of ref document: EP